Clearly our two methods of analysis are not entirely compatible and results of cosinor analysis will give more conservative estimates of amplitude since it takes a balanced view of all the data points whereas calculation from the highest observed daily values is biased towards extremes of variation in the raw data. Moreover, patients in Dr Connolly's study4 achieved a lower overall PEFR (mean values 182 1 min'1 for males and 127 1 min-' in females). At these lower levels the noise to signal ratio is high and amplitude is liable to overestimation in comparison with our subjects with PEFR in the predicted normal range. Unfortunately, these differences between normal subjects and patients constitute an insuperable obstacle to comparison of their PEFR rhythms. Amplitude measured as percenage of the highest daily reading also relies heavily on the accuracy of these few readings whereas cosinor analysis attaches equal weight to all observations. We, therefore, maintain that an amplitude of >20% of the mean value in the PEFR rhythm is a valid threshold above which the diagnosis of asthma should be considered. As a corollary to this, we have previously found that only some 20 % of asthma patients in hospital had amplitudes of >25% measured from raw data as percentages of the highest daily reading.' Thus the threshold for a diagnosis of asthma appears to lie in the range 20-25%. This view is supported by the work of Dawkins and Muers5 who have used cosinor analysis to study PEFR rhythms in chronic bronchitis and obtained similar results to our normal data. What is the best treatment for early operable small cefl carcinoma of the bronchus?
Sir,-We wish to take issue with much of the factual data presented by Dr Levison in his editorial' and to suggest that the proposed national study is not practical and will fail to determine the role of surgery in operable small cell carcinoma of the bronchus (SCCB).
SCCB does not behave in a uniform manner; there is a considerable variability of response to chemotherapy which does not correlate with any obvious histological subtyping. The statement that 95% of SCCB occurs in men is no longer true; more recent reports contain ratios of three or four men to one woman and in the last 300 cases treated by our group 40% were women. The overall incidence is not 36% of all lung cancers, but nearer to 20-25%. 2 Much of the data presented in the editorial come from studies in patients with "limited" disease but it is important to make clear what this term means. It is usually used to describe a category of patients where the disease is confined to one hemithorax and in whom there is no detectable metastatic spread. These patients are rarely "operable". In our study3 sequential staging using CT scanning of thorax and abdomen in 50 consecutive patients showed that all patients were inoperable, 74% having T3 tumours including the three patients who, on chest x-ray, were thought to have TI tumours. In our last 315 patients we have seen one operable case. There is now a considerable body of evidence to show that the median survival of even "limited" disease does not exceed nine months when a local treatment, such as radiotherapy, is used alone. Better results with chemotherapy are achieved in this category of patients,4 5 and it is not yet clear if radiotherapy has any part to play in management other than as a palliative procedure. Early results from randomised trials,6 including our own, suggest that it does not prolong survival in patients treated adequately with drugs.
After high dose radiation relapse in the chest is common,7 8 indicating that local control is rarely achieved and that the suggested preoperative low dose radiotherapy would not render patients operable. It is not appropriate to draw an analogy between "debulking" surgery in ovarian cancer and small cell carcinoma. Ovarian cancer often remains localised in the abdomen and is a slowly growing adenocarcinoma. Small cell carcinoma usually spreads early and grows rapidly. Local surgery is unlikely to influence mortality in this situation.
Cranial irradiation is of no proven benefit for survival in small cell carcinoma and it is not logical to include it in randomised studies until longer survival is achieved than that currently being obtained. Dr Levison's proposed study therefore concerns a tiny minority of patients with small cell carcinoma in whom the tumour is operable. Adequate investigation of these patients will probably reveal more extensive disease in many. Furthermore by having four arms to the study, all of which include surgery, it is certain that the investigation will take many years to complete and that the role of surgery will not have been evaluated. The study design as proposed will assess the role of preoperative low dose radiotherapy and brain irradiation. At Sir,-Thank you for allowing me to see the letter from Dr Souhami and his colleagues. May I take their various points as they arise? 1 I agree that SCCB does not behave in a uniform manner, and that it is not possible to predict the response to chemotherapy from any histological subtyping. This statement is equally applicable to many malignant tumours currently being treated with drugs. The majority of patients with macroscopic SCCB do however respond, albeit temporarily, to chemotherapy and it is therefore logical to attempt the destruction of micrometastases by the same method. I cannot agree that it is not worthwhile to assess the value of preoperative low dose radiotherapy; only a trial can prove or disprove this.
If it could be agreed that the mainstay of a study to ascertain the best treatment for early operable SCCB was surgery, it is surely correct to add to this radiotherapy or chemotherapy or both, which offer the most optimistic approach based on current knowledge; perhaps the use of cranial irradiation could be left open to discussion. 
